drugset / Trial / NCT00414622
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
Timeline
- Start
- 2006-11
- Primary completion
- —
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GTS-21 | Small molecule | 25 mg | — |
| Subject | GTS-21 | Small molecule | 50 mg | — |
| Subject | GTS-21 | Small molecule | 75 mg | — |
| Subject | GTS-21 | Small molecule | 150 mg | — |